John Koreth

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:183-96. 2007
  2. pmc Does iron overload really matter in stem cell transplantation?
    Philippe Armand
    Departments of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Am J Hematol 87:569-72. 2012
  3. ncbi request reprint Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 18:805-12. 2012
  4. pmc Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:3202-8. 2012
  5. pmc Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:3956-9. 2009
  6. pmc Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 15:844-50. 2009
  7. pmc Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 16:792-800. 2010
  8. pmc Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008
  9. doi request reprint Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 19:981-7. 2013
  10. pmc Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 17:1196-204. 2011

Detail Information

Publications49

  1. ncbi request reprint High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:183-96. 2007
    ..01; 95% confidence interval, 1.64-5.50). Hence, evaluating alternative therapeutic options upfront may also be reasonable...
  2. pmc Does iron overload really matter in stem cell transplantation?
    Philippe Armand
    Departments of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Am J Hematol 87:569-72. 2012
    ..These results raise the possibility that the adverse prognostic impact of pre-HSCT hyperferritinemia may be related to factors independent of iron overload...
  3. ncbi request reprint Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 18:805-12. 2012
    ..Our findings suggest that the use of 2 partially matched UCB units appears to be a suitable alternative for patients undergoing RIC HSCT without an HLA-matched donor...
  4. pmc Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:3202-8. 2012
    ..The proteasome inhibitor bortezomib has immunomodulatory properties potentially beneficial for control of GVHD in T-cell-replete HLA-mismatched transplantation...
  5. pmc Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:3956-9. 2009
    ..Bortezomib is a promising novel immunomodulatory agent in allogeneic transplantation. This study was registered at http://www.clinicaltrials.gov as #NCT00369226...
  6. pmc Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 15:844-50. 2009
    ..The omission of mini-MTX from the Tac/Sir GVHD prophylaxis regimen appears to have no adverse effect on the development of aGVHD...
  7. pmc Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 16:792-800. 2010
    ..62, P = .03) associated with poorer PFS. RIC HSCT is well tolerated, with reasonable survival in elderly patients. Age is not associated with impaired outcomes. HSCT should not be excluded solely based on advanced patient age...
  8. pmc Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008
    ..We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression...
  9. doi request reprint Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia
    Yi Bin Chen
    Bone Marrow Transplant Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Blood Marrow Transplant 19:981-7. 2013
    ..2 mg/kg versus 6.4 mg/kg) is not associated with significant differences in overall outcomes...
  10. pmc Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 17:1196-204. 2011
    ..67, P = .002) and superior PFS (HR 0.69, P = .002). These results suggest that URD is associated with greater GVL activity than MRD, and could have practice changing impact on future donor selection in RIC HSCT...
  11. doi request reprint Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 17:421-8. 2011
    ..In summary, we document a high incidence of ES after syngeneic HSCT. The trend of increased NRM after ES requires reevaluation in a larger syngeneic HSCT cohort...
  12. pmc Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis
    Joshua A Hill
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 18:1638-48. 2012
    ..1-17.3; P = .04). Death from HHV-6-PALE occurred in 50% of affected patients undergoing UCBT and no recipients of adult-donor cells. Patients receiving UCBT have increased risk for HHV-6-PALE and greater morbidity from this disease...
  13. pmc Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation
    Caron A Jacobson
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Biol Blood Marrow Transplant 18:565-74. 2012
    ..There is no increased risk of relapse, suggesting that graft-versus-leukemia activity is maintained. Early reconstitution of B cells and NK cells may, in part, account for these findings...
  14. pmc Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease
    Ken Ichi Matsuoka
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Sci Transl Med 5:179ra43. 2013
    ..Low-dose IL-2 had minimal effects on Tcons. These findings define the mechanisms whereby low-dose IL-2 therapy restores the homeostasis of CD4(+) T cell subsets and promotes the reestablishment of immune tolerance...
  15. pmc Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation
    Bradley W Blaser
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 18:575-83. 2012
    ..Given the cardiovascular risk associated with hyperlipidemia and the tolerability of statins, further prospective evaluation of lipid abnormalities and their treatment seems well warranted...
  16. pmc Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation
    Yutaka Kawano
    Division of Hematologic Malignancies and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 118:5021-30. 2011
    ..These results suggest that failure to activate Treg telomerase may restrict proliferative capacity and increase apoptotic susceptibility, resulting in the loss of peripheral tolerance and the development of cGVHD...
  17. pmc Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation
    Ken Ichi Matsuoka
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 120:1479-93. 2010
    ..These studies indicate that CD4+ lymphopenia is a critical factor in Treg homeostasis and that prolonged imbalance of Treg homeostasis after HSCT can result in loss of tolerance and significant clinical disease manifestations...
  18. doi request reprint Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies
    Andrew M Brunner
    Bone Marrow Transplant Unit, Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 19:1374-80. 2013
    ..Nonrelapse mortality was 3.7% at day +100 and 5.6% at 2 years. We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older...
  19. pmc Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation
    Corey Cutler
    Department of Medical Oncology, Division of Hematological Malignancies, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA
    Blood 118:6691-7. 2011
    ..0%, P = .04). We conclude that identification of preformed DSAs in umbilical cord blood recipients should be performed and that the use of umbilical cord blood units where preformed host DSAs exist should be avoided...
  20. pmc Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 112:4425-31. 2008
    ..Sirolimus-based GVHD prophylaxis without methotrexate is associated with the greatest overall survival. Myeloablative doses of busulfan should not be used with sirolimus-based immunosuppression...
  21. pmc A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:28-35. 2008
    ....
  22. pmc Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Blood 122:1510-7. 2013
    ..039). Rituximab can prevent systemic corticosteroid-requiring chronic GVHD after peripheral blood stem cell transplantation and should be tested in a prospective randomized trial...
  23. pmc A disease risk index for patients undergoing allogeneic stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Blood 120:905-13. 2012
    ....
  24. pmc Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 17:852-60. 2011
    ..These results contribute to our understanding of the prevalence, mechanism, and consequences of iron overload in HSCT...
  25. pmc Interleukin-2 and regulatory T cells in graft-versus-host disease
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02215, USA
    N Engl J Med 365:2055-66. 2011
    ..Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD...
  26. pmc Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease
    Sarah Nikiforow
    Division of Hematologic Malignancies, Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Biol Blood Marrow Transplant 19:804-11. 2013
    ..The pattern of lymphocyte recovery after alemtuzumab will inform the biology and future therapy of cGVHD. The use of alemtuzumab in the context of therapy for cGVHD deserves study in larger phase II trials...
  27. pmc Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease
    Caron A Jacobson
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    Biol Blood Marrow Transplant 20:668-75. 2014
    ..Taken together, our results are important for interpreting BAFF measurements in cGVHD biomarker studies. ..
  28. pmc Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
    ..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...
  29. pmc Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
    Francisco M Marty
    Division of Infectious Diseases, Boston, MA 02115, USA
    Blood 110:490-500. 2007
    ..66; P = .14 and P = .35, respectively). The protective effect of sirolimus-containing GVHD prophylaxis regimens on CMV reactivation should be confirmed in randomized trials...
  30. pmc Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
    Akiko M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 14:197-207. 2008
    ..If no complications occurred, the mean cost within the first year was $79,222. These results provide cost estimates for complicated and uncomplicated HDCT procedures, as well as costs for management of specific transplant complications...
  31. pmc Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients
    Nicolas C Issa
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 17:434-8. 2011
    ..11; 95% confidence interval, 0.01-0.97). The vaccine was safe and well tolerated. Strategies are needed to improve the influenza vaccine response in this population, especially those receiving immunotherapy...
  32. pmc Prediction of veno-occlusive disease using biomarkers of endothelial injury
    Corey Cutler
    Division of Hematologic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 16:1180-5. 2010
    ..We conclude that vWF, thrombomodulin, and sICAM-1 elevations before and early after transplantation may be useful in predicting VOD in patients receiving sirolimus...
  33. pmc Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:3865-74. 2009
    ..These studies delineate specific abnormalities of B-cell homeostasis in patients with cGVHD and suggest that BAFF targeting agents may be useful in this disease...
  34. pmc Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation
    Vincent T Ho
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:15825-30. 2009
    ....
  35. pmc White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome
    Haesook T Kim
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts
    Am J Hematol 89:591-7. 2014
    ..If validated, this system could be useful in the clinical management of patients after HCT, and to stratify patients enrolled on HCT clinical trials...
  36. pmc Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation
    Corey Cutler
    Dana Farber Cancer Institute, Boston, MA
    Blood 122:3074-81. 2013
    ..We observed encouraging trends in efficacy, with accelerated neutrophil recovery (17.5 vs 21 days, P = .045), coupled with preferential, long-term engraftment of the dmPGE2-treated UCB unit in 10 of 12 treated participants...
  37. pmc Donor-derived second hematologic malignancies after cord blood transplantation
    Karen K Ballen
    Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Biol Blood Marrow Transplant 16:1025-31. 2010
    ..Second myelogenous malignancies of donor origin occur after double UCBT, suggesting that a search for donor origin should be performed in all patients with suspected relapse...
  38. pmc Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:4586-8. 2007
    ..They also suggest future prospective trials to examine the potential benefit of chelation therapy in this setting...
  39. pmc Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells
    Ute E Burkhardt
    Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 123:3756-65. 2013
    ..We conducted a prospective clinical trial to test whether vaccination with whole leukemia cells early after transplantation facilitates the expansion of leukemia-reactive T cells and thereby enhances antitumor immunity...
  40. pmc Phase II trial of parathyroid hormone after double umbilical cord blood transplantation
    Karen Ballen
    Hematology Oncology Division, Department of Medicine, Massachusetts General Hospital, Boston, USA
    Biol Blood Marrow Transplant 18:1851-8. 2012
    ..Overall survival at 6 months after transplantation was 62%, and disease-free survival at 2 years was 39%. At the dose and schedule studied, there was no evidence that PTH influenced blood count recovery...
  41. pmc Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    JAMA 301:2349-61. 2009
    ..Allogeneic SCT, autologous transplantation, and consolidation chemotherapy are considered of equivalent benefit for intermediate-risk AML...
  42. pmc Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis
    John Koreth
    Dana Farber Cancer Institute, D1B05, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 31:2662-70. 2013
    ..We evaluated RIC transplantation versus nontransplantation therapies in older patients with MDS stratified by International Prognostic Scoring System (IPSS) risk...
  43. doi request reprint Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant
    Karen K Ballen
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Blood 119:1972-80. 2012
    ..In this review, we discuss the rationale for donor choice and the need of phase 3 studies to help answer this important question...
  44. pmc Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachustts, USA
    Biol Blood Marrow Transplant 15:1502-12. 2009
    ....
  45. doi request reprint Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes
    Gregory A Abel
    Division of Hematologic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Curr Opin Hematol 20:150-6. 2013
    ....
  46. pmc Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis
    Julia A Brown
    Department of Medicine, Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Blood 115:4111-9. 2010
    ..The trial was prospectively registered at http://www.clinicaltrials.gov (NCT00133367)...
  47. ncbi request reprint Multiple myeloma in a 50-year-old with an HLA-identical sibling
    John Koreth
    Dana Farber Cancer Institute, Division of Hematologic Malignancies, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 13:1247-8. 2007
  48. pmc Current and future approaches for control of graft-versus-host disease
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Expert Rev Hematol 1:111. 2008
    ..This article reviews the current state of knowledge regarding the prevention and treatment of acute and chronic GVHD. Novel approaches currently undergoing evaluation are also highlighted...
  49. pmc Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation
    Corey Cutler
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:3108-14. 2007
    ..Differences between MRD and URD cohorts are not evident when effective GVHD prophylaxis is used...